Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTB-268 in Moderately to Severely Active Ulcerative Colitis
NCT06109441Phase 2Active, not recruiting
- Sponsor
- AltruBio Inc.
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of leiolizumab in ulcerative colitis (UC), sponsored by AltruBio Inc.. Started Dec 2023; status: active, not recruiting.
02
Drugs
leiolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06109441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109441.